We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SCI Files Patents Relating to Production of Human Motor Neurons and Progenitors
News

SCI Files Patents Relating to Production of Human Motor Neurons and Progenitors

SCI Files Patents Relating to Production of Human Motor Neurons and Progenitors
News

SCI Files Patents Relating to Production of Human Motor Neurons and Progenitors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SCI Files Patents Relating to Production of Human Motor Neurons and Progenitors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Innovations, Inc. has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons.

These cells will initially be used in the Company's core drug discovery and toxicology platform. The Company is also exploring therapeutic applications of these cells.

Dr. James Kelly, CEO of Stem Cell Innovations, Inc, stated, "These cells have significant potential in both drug discovery and cell therapies to treat diseases such as ALS, Parkinson's, Huntington's, Multiple Sclerosis, and Spinal Cord Injury."

"Obtaining and protecting neural progenitor cells, as well as purified populations of motor neurons from our PCs, is a significant step for the company."

Kelly added, "We are already in discussions with companies that have expressed interest in these cells."

Advertisement